TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (the “Company”) announces it has renewed its at-the-market equity program (“ATM Program”) that allows the Company to issue shares of the Company to the public from time to time at the Company’s discretion, effective until July 19, 2027 unless terminated prior to such date by the Company. This ATM Program replaces the prior program established in January 2024 that has terminated. Any Class A Shares or Preferred Shares sold in the ATM Program will ...

OTCQB ticker symbol to change to VRSSDVANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) ("VERSES'' or the "Company”), a cognitive computing company specializing in next-generation agentic software systems, announces the Company is consolidating all of its issued and outstanding Class A Subordinate Voting Shares (the “Subordinate Voting Shares”) on the basis of one (1) post-consolidated Subordinate Voting Share for every three (3) pre-consolidated Subor ...

Core Insights - Actuate Therapeutics, Inc. announced promising biomarker data from the Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line metastatic pancreatic adenocarcinoma, highlighting the potential for improved patient stratification based on pre-dose plasma biomarkers [1][2][3] Group 1: Study Findings - The analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors identified 7 significant biomarkers predicting favorable survival in the elraglusib-treated cohort, particularly highlighting CXCL2's unique survival trend [2][3] - Univariate analysis showed that elevated levels of CXCL2 and TRAIL were associated with improved overall survival, while lower levels of CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3 were linked to better survival outcomes [3] - Multivariate machine learning models were developed to accurately predict patients likely to survive over one year when treated with elraglusib and GnP [3] Group 2: Company Strategy and Future Plans - The results support the use of non-invasive blood-based markers to identify patients who may benefit from elraglusib, indicating a significant advancement in the company's biomarker strategy [4] - The company plans to prospectively test the identified biomarkers in future trials and focus on optimizing patient stratification and predictive accuracy through refined machine learning models [4] - Actuate aims to apply this biomarker identification approach to guide the development of elraglusib in metastatic pancreatic cancer and other advanced cancer indications [4] Group 3: Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with elraglusib as its lead investigational drug targeting pathways involved in tumor growth and resistance to conventional therapies [5] - Elraglusib may also enhance anti-tumor immunity by regulating immune checkpoints and immune cell functions, indicating its potential in cancer treatment [5]

Core Points - Orange S.A. has announced the results of a tender offer to repurchase part of two series of outstanding hybrid notes, specifically the NC 2026 and NC 2027 Existing Notes [1][2] - The settlement of the tender offer is expected to occur on June 24, 2025 [2] Summary of Tender Offer Results - For the NC 2026 Existing Notes: - The total principal amount validly tendered is €743,530,000 - The Series Acceptance Amount is €600,002,000 - The Tender Price is 103.147% [6] - For the NC 2027 Existing Notes: - The total principal amount validly tendered is €274,800,000 - The Series Acceptance Amount is €150,000,000 - The Tender Price is 98.336% [6] Company Overview - Orange is a leading telecommunications operator with revenues of €40.3 billion in 2024 and a workforce of 125,800 employees worldwide as of March 31, 2025 [8] - The company serves a total customer base of 294 million, including 256 million mobile customers and 22 million fixed broadband customers [8] - Orange operates in 26 countries and is also a significant provider of global IT and telecommunication services to multinational companies under the brand Orange Business [9]

Core Viewpoint - VivoPower International PLC has successfully closed the first phase of a US$121 million investment round, raising US$60.5 million, led by His Royal Highness Prince Abdulaziz bin Turki bin Talal Al Saud and a consortium of non-U.S. investors [1][2] Group 1: Investment Details - The first phase of the investment round is part of a larger strategy to support VivoPower's treasury and decentralized finance solutions, focusing on Ripple and XRP [2][5] - The remaining 50% of the investment is expected to close soon, pending shareholder approval to increase authorized share capital [2] Group 2: Company Transformation - VivoPower is undergoing a strategic transformation to become the world's first XRP-focused digital asset enterprise, emphasizing the acquisition and management of XRP digital assets [5] - The company aims to enhance the growth and utility of the XRP Ledger by supporting decentralized finance infrastructure and real-world blockchain applications [5] Group 3: Company Background - Founded in 2014 and listed on Nasdaq since 2016, VivoPower operates globally across various regions including the UK, Australia, North America, Europe, the Middle East, and Southeast Asia [6] - VivoPower is recognized as a sustainable energy solutions B Corporation, with two main business units: Tembo, focusing on electric solutions for ruggedized fleet applications, and Caret Digital, which is centered on renewable power use cases including digital asset mining [6]

Group 1 - The company Kaldvík AS has announced an extraordinary general meeting to consider a proposal for an investigation, scheduled for 4 July 2025 at 12:00 hours (CEST) [1] - The meeting will be conducted digitally through Lumi AGM, and shareholders are encouraged to pre-register their attendance or provide a proxy [2] - The deadline for pre-registration and proxy registration is set for 2 July 2025 at 12:00 hours (CEST) [2] Group 2 - Contact information for further inquiries includes CEO Roy-Tore Rikardsen and CFO Robert Robertsson, with mobile numbers provided [3] - The announcement is subject to the disclosure requirements under Section 5-12 of the Norwegian Securities Trading Act [3]

Core Viewpoint - Emrosi™ has demonstrated efficacy in treating moderate-to-severe papulopustular rosacea, independent of body weight differences, supporting its FDA approval in November 2024 [1][6][8] Group 1: Clinical Trial Results - Data from two Phase 3 trials (MVOR-1 and MVOR-2) showed that Emrosi can be prescribed without regard to body weight, reducing potential dosing errors [2][5] - In MVOR-1, 75.5% of subjects with body weight ≤ median achieved IGA treatment success with Emrosi compared to 51.0% with doxycycline and 28.2% with placebo [4] - In MVOR-2, 65.0% of subjects with body weight > median achieved IGA treatment success with Emrosi compared to 33.9% with doxycycline and 22.6% with placebo [4] Group 2: Efficacy and Safety - Emrosi showed superior efficacy on both co-primary endpoints compared to placebo and doxycycline, with no significant differences in adverse events reported [5][6] - The most common adverse reaction was dyspepsia, occurring in ≥1% of subjects treated with Emrosi [9] Group 3: Company Overview - Journey Medical Corporation focuses on marketing FDA-approved prescription products for dermatological conditions and currently markets eight such products [11] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [11]

Company Overview - Gaia, Inc. is a conscious media and community company that operates a global video streaming service, producing and curating content across four primary channels: Seeking Truth, Transformation, Alternative Healing, and Yoga [3] - The service is available in four languages (English, Spanish, French, and German) and serves members in 185 countries [3] - Gaia's library includes over 10,000 titles, with more than 88% being exclusive to the platform, and approximately 75% of viewership is generated by content produced or owned by Gaia [3] Upcoming Events - Gaia's management will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 on June 24 and 25, 2025 [1] - CEO James Calhoun and CFO Ned Preston will deliver a company presentation on June 24, followed by one-on-one meetings with investors on June 25 [1][2] Investor Engagement - The iAccess Alpha conferences feature companies recommended by investors, including webcast presentations on Day 1 and one-on-one meetings on Day 2 [2] - Interested parties can register and schedule meetings with Gaia through the conference website [2]

SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided an update on the expected timing for the closing of its previously announced acquisition of Yerbaé Brands Corp. (TSX-V: YERB.U) (“Yerbaé”). Following the approval of the acquisition by a majority of its stockholders on June 12, 2025, the companies have been working to complete the final administrative steps for the transaction. While the closing was anticipated this week, the pr ...

Vancouver, BC, June 20, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $2,250,000 (the “Private Placement”). The Private Placement attracted participation from two strategic institutional investors. Trident has allotted and issued 3,000,000 units (the “Units”) at a price of CAD $0.75 per Unit. Each Unit is comprised of one flow-through common sha ...